(Alliance News) – Poolbeg Pharma PLC announced on Wednesday that its Immunomodulator I patent has been granted in the United States.
The London-based clinical-stage biopharmaceutical company, which targets diseases with unmet medical needs, said the patent covers Poolbeg’s POLB 001 asset and other p38 mitogen-activated protein kinase inhibitors .
POLB 001 is a treatment for patients at risk of severe flu after an immune response is triggered, as well as a treatment for hypercytokinemia, or cytokine storm, a feature of severe flu that develops when the system The immune system responds to infection or immunotherapy drugs more aggressively than it should.
Jeremy Skillington, Managing Director, said: “This decision by the US Patent Office further strengthens the [propriété intellectuelle] of our lead development candidate, POLB 001. Strong intellectual property is the foundation of value creation in the biopharmaceutical sector and, with each new patent, we not only protect our asset, but also increase the commercial attractiveness of POLB 001 for potential partners.
“We are excited about POLB 001’s potential to address critical unmet medical needs and we remain focused on high-value programs and partnerships to develop and commercialize our assets.”
Poolbeg Pharma shares closed 3.8% lower at 7.60 pence each in London on Wednesday.
By Emily Parsons, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
What specific diseases is Poolbeg Pharma targeting with its pipeline of assets, and how do you prioritize which ones to develop first?
Question 1: Can you provide an overview of Poolbeg Pharma and its approach to developing treatments for diseases with unmet medical needs?
Guest 1: Of course! Poolbeg Pharma is a London-based clinical-stage biopharmaceutical company that focuses on developing treatments for diseases with unmet medical needs. Our unique approach involves identifying promising drug candidates that have the potential to address these urgent health issues and advancing them through clinical trials to bring new therapies to patients. We have a diverse pipeline of assets targeting various diseases, including respiratory diseases, inflammatory diseases, and infectious diseases.
Guest 2: We at Poolbeg Pharma strongly believe in innovation and we are committed to leveraging our expertise in drug development to bring novel treatments to patients who are suffering from serious conditions with limited treatment options. Our strategy is to identify promising targets and develop small molecule therapies that can modulate the immune system to address various diseases, including cancer and infectious diseases.
Question 2: Congratulations on the recent patent grant for your Immunomodulator I in the United States. Can you discuss the significance of this achievement and how it will impact your ongoing development efforts?
Guest 1: Thank you! This grant is a significant milestone for us as it provides broad patent protection for our lead asset, POLB 001, as well as other p38 mitogen-activated protein kinase inhibitors. The patent will be essential in securing the commercial value of POLB 001 and enhancing our partnership opportunities. We are particularly excited about the potential for this drug to treat patients at risk of severe flu after an immune response has been triggered, as well as those experiencing hypercytokinemia, a severe flu complication.
Guest 2: Absolutely, Jeremy. This patent grant is an important validation of our R&D efforts and it reinforces our intellectual property position in this field. It provides us with the confidence to move forward with our clinical development plans and potentially partner with other organizations to bring POLB 001 to market. We believe this asset has the potential to address critical unmet medical needs, and we are committed
